Alembic Pharmaceuticals Ltd. announced a 16% increase in revenue, reaching ₹1,910 Cr, and a 20% growth in Profit After Tax (PAT) for Q2 FY26. EBITDA increased by 26% to ₹325 Cr with a margin of 17%. The company’s performance reflects strong momentum in core businesses and disciplined execution, supported by a 10% revenue investment in R&D.
Financial Performance Highlights
Alembic Pharmaceuticals Limited reported its consolidated financial results for the second quarter and half year ended September 30, 2025. Key highlights include:
- Revenue from operations increased by 16% to ₹1,910 Cr.
- EBITDA increased by 26% to ₹325 Cr.
- EBITDA Margin at 17% of revenue.
- Reported Profit After Tax at ₹185 Cr, up by 20%.
Management Commentary
According to Mr. Shaunak Amin, MD of Alembic Pharmaceuticals Limited, the company’s Q2 performance reflects continued momentum in core businesses and disciplined execution. The company has strengthened its presence across key markets, maintaining a sharp focus on profitability and operational excellence. Alembic’s R&D investment remains around 10% of revenue, reinforcing its commitment to building a strong pipeline for future growth.
Operational Performance
Key operational highlights include:
India Branded Business
- India Branded Business delivered a 5% YoY growth, reaching ₹639 Cr in revenue for the quarter.
- Gynaecology, Ophthalmology, and Animal healthcare segments have demonstrated accelerating performance.
- Cough & Cold segments grew in line with market performance, with robust operational execution.
- Successfully introduced 2 new products during the quarter.
International Business
- US Generics grew by 21% to ₹566 Cr for the quarter.
- Launched 3 products in the US market during the quarter.
- Ex-US International Generics grew by 31% to ₹392 Cr for the quarter.
- Received 6 ANDA approvals during the quarter, bringing the cumulative ANDA approvals to 226.
API Business
- API business grew by 15% to ₹261 Cr for the quarter.
Revenue Summary
The following table summarizes the total revenue:
| Particulars | Q2 FY26 | Q2 FY25 | % Change | H-1 FY26 | H-1 FY25 | % Change |
| Formulation | ||||||
| India | 639 | 609 | 5% | 1238 | 1181 | 5% |
| USA | 566 | 467 | 21% | 1089 | 928 | 17% |
| Ex- US | 392 | 298 | 31% | 719 | 568 | 27% |
| API | 314 | 274 | 15% | 575 | 532 | 8% |
| Total | 1910 | 1648 | 16% | 3621 | 3210 | 13% |
Earnings Call Information
Alembic Pharmaceuticals Limited will host an investor call at 4:30 pm IST on August 5, 2025, to discuss the company’s performance and answer questions from participants.
Source: BSE